Inhibrx Biosciences (INBX) Amortization of Deferred Charges (2023 - 2025)
Inhibrx Biosciences (INBX) reported Amortization of Deferred Charges of $642000.0 for Q4 2025, up 0.63% quarter-over-quarter from $638000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Amortization of Deferred Charges (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Amortization of Deferred Charges data on file, last reported at $642000.0 in Q4 2025.
- Amortization of Deferred Charges for Q4 2025 came in at $642000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $2.4 million (up 18.11% YoY), and the FY2025 annual result was $2.4 million, up 18.11% from the prior year.
- Amortization of Deferred Charges advanced to $642000.0 in Q4 2025 per INBX's latest filing, from $638000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $1.2 million in Q4 2023 and troughed at $533000.0 in Q1 2025.
- A 3-year average of $873750.0 and a median of $732500.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- On a YoY basis, Amortization of Deferred Charges climbed as much as 23.94% in 2025 and fell as far as 57.09% in 2025.
- A 3-year view of Amortization of Deferred Charges shows it stood at $1.2 million in 2023, then slumped by 34.0% to $823000.0 in 2024, then declined by 21.99% to $642000.0 in 2025.
- Business Quant data shows INBX's Amortization of Deferred Charges at $642000.0 in Q4 2025, $638000.0 in Q3 2025, and $626000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 642,000.00 |
| Dec 31, 2025 | 642,000.00 |
| Sep 30, 2025 | 638,000.00 |
| Sep 30, 2025 | 638,000.00 |
| Jun 30, 2025 | 626,000.00 |
| Jun 30, 2025 | 626,000.00 |
| Mar 31, 2025 | 533,000.00 |
| Mar 31, 2025 | 533,000.00 |
| Jun 30, 2024 | 823,000.00 |
| Jun 30, 2024 | 823,000.00 |
| Mar 31, 2024 | 1.24 Mn |
| Mar 31, 2024 | 1.24 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Sep 30, 2023 | 1.24 Mn |
| Sep 30, 2023 | 1.24 Mn |